Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
CAR T-Cell Therapies and Survival Outcomes Among Patients With R/R FL
12/03/2025
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to...
12/03/2025
Oncology
Quiz
Relmacabtagene Autoleucel for R/R Follicular Lymphoma
10/30/2025
Emily Estrada
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily...
10/30/2025
Oncology
Quiz
Amulirafusp Alfa Plus Lenalidomide for R/R FL
09/24/2025
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a...
09/24/2025
Oncology
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology
Quiz
Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma
03/27/2024
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to...
03/27/2024
Oncology
Quiz
Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy
02/05/2024
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from...
02/05/2024
Oncology
Quiz
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL
01/29/2024
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the...
01/29/2024
Oncology
Quiz
Second-Line Treatment Outcomes Among Patients With FL or MZL
12/07/2023
True or False: According to a 7-year follow-up of the phase 3 SELENE study, the overall survival in the ibrutinib-chemotherapy arm and placebo chemotherapy arm were promising, which indicates encouraging outcomes among patients in the second...
True or False: According to a 7-year follow-up of the phase 3 SELENE study, the overall survival in the ibrutinib-chemotherapy arm and placebo chemotherapy arm were promising, which indicates encouraging outcomes among patients in the second...
True or False: According to a...
12/07/2023
Oncology
Quiz
Treating Non-Hodgkin Lymphoma With Re-Priming Radiation Therapy After CAR T
11/14/2023
True or False: Results from a phase 1 trial on re-priming radiation therapy for R/R non-Hodgkin lymphoma, including DLBCL and FL, indicated that early salvage focal definitive dose radiation to sites of incomplete response after CAR T-cell...
True or False: Results from a phase 1 trial on re-priming radiation therapy for R/R non-Hodgkin lymphoma, including DLBCL and FL, indicated that early salvage focal definitive dose radiation to sites of incomplete response after CAR T-cell...
True or False: Results from a...
11/14/2023
Oncology
Quiz
Measuring Risk of Therapy-Related Myeloid Neoplasms Among Patients With FL or DLBCL
11/06/2023
True or False: Findings from a 15-year SEER-Medicare study identified that prior histories of autoimmunity and the use of granulocyte colony-stimulating factors significantly decreased the risk of development of therapy-related...
True or False: Findings from a 15-year SEER-Medicare study identified that prior histories of autoimmunity and the use of granulocyte colony-stimulating factors significantly decreased the risk of development of therapy-related...
True or False: Findings from a...
11/06/2023
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use